The global Pharmacovigilance (PV) Market size is estimated to reach USD 10.27 billion by 2025, registering at a 13.1% CAGR over the forecast period as the scope and its applications are rising enormously across the globe. Pharmacovigilance (PV) is also termed as drug safety, is a science and activities relating to the prevention, detection, understanding, and assessment of adverse effects or other drug-related issues. The factors that are playing a major role in the growth of pharmacovigilance market are the rising occurrence of adverse drug reactions (ADR), enhancement in development of ADR database and information system, and the rising demand from the end-users. Pharmacovigilance (PV) industry is segmented based on the clinical trial phase, service provider, type of methods, end-user, and region. Phase IV, phase III, phase II, phase I, and pre-clinical are the clinical trial phase that could be explored in pharmacovigilance (PV) market in the forecast period. The phase IV sector...
According to new report available with marketsandtrendsreport, We provide market research report within-depth analysis of market by production, share, size, demand, economic trends, investment feasibility, major key players, analysis and forecast.